Stock Events

Stock Events

Sutro Biopharma 

$20.61
43
-$1.30-5.93% 19:12 Today

Statistics

Day High
22.14
Day Low
20.45
52W High
43.85
52W Low
7.15
Volume
70,910
Avg. Volume
364,559
Mkt Cap
341.74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-6.7
-4.51
-2.33
-0.14
Expected EPS
-1.663571
Actual EPS
N/A

Financials

-186.45%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
102.48MRevenue
-191.09MNet Income

Analyst Ratings

47.22Average Price Target
The highest estimate is 60.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow STRO. It's not an investment recommendation.
Microsoft
10
MSFT
Amazon
10
AMZN
Apple
9
AAPL
Tesla
9
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adaptive Biotechnologies
ADPT
Mkt Cap3.94B
Adaptive Biotechnologies focuses on immune-driven medicines, directly competing in the biopharma space with similar technological approaches as Sutro Biopharma.
Xencor
XNCR
Mkt Cap1.74B
Xencor operates in the development of engineered monoclonal antibodies, a direct competitor to Sutro's antibody-drug conjugate and bispecific antibody platforms.
Allogene Therapeutics
ALLO
Mkt Cap708.26M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, competing in the innovative cancer treatment space alongside Sutro Biopharma.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge technology that competes with Sutro's platform for developing cancer and autoimmune therapies.
Novartis
NVS
Mkt Cap286.78B
Novartis is a large pharmaceutical company with a broad portfolio that includes advanced biopharmaceuticals, competing across multiple areas including oncology, where Sutro is active.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical focuses on rare diseases using advanced biotechnologies, competing for similar patient populations and biotech innovation space as Sutro.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is known for its monoclonal antibodies and other biopharmaceuticals, directly competing in the therapeutic areas targeted by Sutro Biopharma.
AMGEN
AMGN
Mkt Cap224.63B
Amgen, a biotechnology pioneer, competes across a range of therapeutic areas, including oncology and inflammation, overlapping with Sutro's focus areas.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, with its strong focus on antiviral drugs and cancer therapies, competes in the development of innovative treatments in areas that overlap with Sutro Biopharma's interests.

About

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Show more...
CEO
Jane Chung
Employees
128
Country
United States
ISIN
US8693672011
WKN
000A41VMF

Listings

STU
DE
S090.STU
MU
DE
S090.MU
XNAS
US
STRO
F
DE
S090.F

0 Comments

Share your thoughts

FAQ

What is Sutro Biopharma stock price today?▼
The current price of STRO is $20.61 USD — it has decreased by -5.93% in the past 24 hours. Watch Sutro Biopharma stock price performance more closely on the chart.
What is Sutro Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Sutro Biopharma stocks are traded under the ticker STRO.
Is Sutro Biopharma stock price growing?▼
STRO stock has fallen by -3.59% compared to the previous week, the month change is a -9.05% fall, over the last year Sutro Biopharma has showed a +137.65% increase.
What is Sutro Biopharma market cap?▼
Today Sutro Biopharma has the market capitalization of 341.74M
When is the next Sutro Biopharma earnings date?▼
Sutro Biopharma is going to release the next earnings report on November 11, 2026.
What were Sutro Biopharma earnings last quarter?▼
STRO earnings for the last quarter are -2.33 USD per share, whereas the estimation was -2.19 USD resulting in a -6.2% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sutro Biopharma revenue for the last year?▼
Sutro Biopharma revenue for the last year amounts to 102.48M USD.
What is Sutro Biopharma net income for the last year?▼
STRO net income for the last year is -191.09M USD.
How many employees does Sutro Biopharma have?▼
As of August 20, 2026, the company has 128 employees.
In which sector is Sutro Biopharma located?▼
Sutro Biopharma operates in the Health & Wellness sector.
When did Sutro Biopharma complete a stock split?▼
The last stock split for Sutro Biopharma was on December 03, 2025 with a ratio of 1:10.
Where is Sutro Biopharma headquartered?▼
Sutro Biopharma is headquartered in SOUTH SAN FRANCISCO, United States.